Loading company…
Sublimity Therapeutics develops biologic therapies for autoimmune diseases using a unique delivery system.
Its therapies aim to improve patient adherence and treatment effectiveness, and its products are positioned in Europe and North America. Founded in 2000 and headquartered in Dublin, Ireland, the company is at the Series B stage and raised EUR 1.09 mn in Series B funding from HBM Partners in August 2020.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in